Kerr, C.R., Connolly, S.J., Kowey, P., Page, R.L., Pritchett, E.L., Ruda, M.Y., et al., A-STAR Investigators (2006) Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. American Journal of Cardiology, 98, 215-218. doi:10.1016/j.amjcard.2006.01.084

has been cited by the following article:

• TITLE: Novel therapies for treating atrial fibrillation

  AUTHORS: Raj Parikh, Philip J. Kadowitz

  KEYWORDS: Atrial Fibrillation; Atrial Flutter; Arrhythmia;Anticoagulation; Stroke

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.4, October 30, 2012

  ABSTRACT: Atrial fibrillation is the most common cardiac arrhythmia and is a major risk factor for stroke, heart failure, and death. Current treatments focus on anti-coagulation as well as rate-control and rhythm-control strategies. Frequent INR checks associated with warfarin along with several adverse side effects of anti-arrhythmics have propelled investigations into novel treatments for atrial fibrillation. Research is focused not only on pioneering new pharmacological antico- agulation and anti-arrhythmic agents but also on improving surgical techniques in hopes of treating the arrhythmia. Here, we first briefly discuss the current treatment options, both pharmacological and non-pharmacological, for atrial fibrillation. We then present a focused review of recent animal and human investigations that examine the use of novel an-ticoagulation agents, mechanisms of new anti-arrhythmics, analyze potential triggers of atrial fibrillation, and highlight the role of genetics in atrial fibrillation.